Future oncology (London, England) · 2021
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shore Neal, Ionescu-Ittu Raluca, Yang Lingfeng, Laliberté François, Mahendran Malena, Lejeune Dominique, Yu Louise, Burgents Joseph, Duh Mei Sheng, Ghate Sameer R
Аннотация
Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.
Предметные рубрики MeSH
Academic Medical CentersAgedAged, 80 and overBiomarkers, TumorCancer Care FacilitiesClinical Decision-MakingCommunity Health CentersDNA RepairGenetic TestingHumansMaleMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsPractice Patterns, Physicians'Precision MedicineProstatic Neoplasms, Castration-Resistant